Everything below concerns actin-binding motif. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-11-16. Numbers and descriptions here follow the published literature rather than marketing material.
Literature and online discussion often conflate TB-500 with full-length thymosin beta-4, even though the two differ in size and are not interchangeable in analytical terms. The fragment is produced by solid-phase peptide synthesis, and the product is a defined seven-residue chain rather than a biological extract. Because the term is a trade-style label, two vendors may supply materials of the same nominal sequence but different counter-ion content, purity, or water content. Comparisons across studies are therefore difficult unless the exact sequence and purity are reported.
TB-500 is a research peptide whose sequence matches residues 17 to 23 of thymosin beta-4, a 43-residue protein present in most mammalian cells. The chain is seven amino acids long, written as LKKTETQ, and is normally supplied with an acetyl group on the N-terminus. Suppliers list it as a lyophilised powder under the code name TB-500, and the same sequence appears elsewhere in catalogues as the thymosin beta-4 actin-binding fragment. The label is commercial rather than systematic, so no single authority fixes exactly what TB-500 denotes.
Interest in the peptide grew during the 2000s and 2010s, when studies of tendon and ligament injuries in horses reported changes in lesion size after treatment. Those reports circulated widely outside the scientific literature and shaped much of the current online discussion. Subsequent reviews noted inconsistent study design, small groups, and a shortage of independent replication. Popular descriptions often blur the line between the fragment, the complete protein, and unrelated growth factors, which complicates comparisons across sources.
TB-500 is a synthetic peptide whose sequence corresponds to a short fragment near the N-terminus of thymosin beta-4, a small protein present in most mammalian cells. The fragment is commonly cited as containing the actin-binding region of the parent molecule, which is why it appears in laboratory work on cell migration and tissue repair. Suppliers distribute it as a lyophilised powder intended for research use. Its identity is defined by amino acid sequence and by the presence of an acetyl group on the N-terminal residue.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Supplied as a lyophilised cake in sealed vials |
| Solubility class | Freely soluble in water | Polar and charged side chains dominate the sequence |
| Typical storage temperature | -20 °C or below | Dry and dark; a desiccant is often recommended |
| Identity confirmation | Mass spectrometry | Observed mass compared with the theoretical value |
| Common synonyms | Thymosin beta-4 fragment | Also written as T beta 4 fragment 17-23 |
Thymosin beta-4 contains 43 amino acids and has a reported molecular mass near 4963 Da. The short fragment most often associated with the TB-500 label, an acetylated chain beginning LKKTETQ, has a reported mass near 889 Da, so the two are easily separated in analytical work. Mass spectrometry and amino acid analysis can confirm which material is present in a given sample. Statements treating TB-500 and thymosin beta-4 as interchangeable are therefore imprecise, even though the two appear together in much of the same literature.
Interest in the compound comes largely from studies of the parent protein, which participates in actin sequestration, cell migration and tissue repair processes. Whether a short fragment reproduces those activities is a separate question that remains open in the published record. Many summaries describe mechanisms by analogy to thymosin beta-4 rather than from direct measurements on the fragment. Claims about activity should be treated as provisional unless a cited study specifies the exact peptide, its purity and the assay used.
TB-500 is a laboratory label applied to a short synthetic peptide that is widely described as a fragment of thymosin beta-4, an actin-binding protein present in most mammalian cells. Suppliers and review articles usually present TB-500 as the N-terminal region of that protein, but the exact sequence attached to the name is not consistent across sources. Some product descriptions list a seven-residue chain; others use the label loosely for the parent protein itself. Because of that variation, any technical discussion of TB-500 needs to state which sequence is meant.
Discussion of TB-500 appears in several distinct literatures that rarely cite one another. Peer-reviewed studies usually describe in vitro assays or small animal experiments and are cautious about extrapolation. Veterinary and sports communities circulate anecdotal reports with limited methodological detail. Commercial listings add a third layer, often using the name interchangeably with thymosin beta-4 even though the two molecules differ in size and sequence. Regulatory status varies by country, and the compound is not a licensed medicine in most jurisdictions, so readers comparing sources should check which molecule and which purity each source actually describes.
TB-500 is a synthetic seven-residue peptide whose sequence, LKKTETQ, matches the N-terminal actin-binding region of thymosin beta-4. It is usually supplied in an N-terminally acetylated form, a modification that blocks the free amino terminus and can influence behavior in solution. In the research literature the same sequence appears under several names, including thymosin beta-4 fragment and shortened thymosin beta-4. Because it is a short peptide rather than the full 43-residue parent protein, its measured properties differ from those reported for thymosin beta-4 as a whole, and the two are not interchangeable in experimental design.
Material sold under this label typically arrives as a freeze-dried powder in a sealed vial with a certificate of analysis. Such certificates usually report reversed-phase chromatography purity plus a mass confirmation, and stated purities commonly sit between 95 and 99 percent. Counter-ion identity, residual trifluoroacetate, water content, and peptide net weight are separate specifications that a certificate may or may not include. A purity figure alone does not establish sequence identity, so independent mass verification remains the practical check.
The designation TB-500 circulates in laboratory and catalog contexts without a single agreed definition. Most product listings apply it to an N-terminally acetylated seven-residue fragment of thymosin beta-4, while other listings attach the same label to the full 43-residue protein. Because the term is commercial rather than systematic, two entries bearing identical names may describe different molecules. Any documentation should therefore state which sequence a given sample is claimed to contain.
Proposed activity centers on actin sequestration and on the movement of cells during repair processes. In cell culture and animal models, the fragment has been associated with migration, tube formation, and tissue remodeling. These observations are frequently described as preliminary, because most published work uses rodent or in vitro systems rather than controlled human trials. Whether the short fragment reproduces the effects of the full protein remains an open question, and the relationship between dose, route, and measured outcome is not well characterized.
The compound circulates in the literature as a research reagent rather than an approved therapeutic. Regulatory agencies in several countries have not authorized it for medical use, and sporting bodies list related thymosin beta-4 peptides among prohibited substances. Suppliers typically market it with a purity figure and a certificate of analysis, while peer-reviewed clinical reports remain sparse. Discussions therefore often separate laboratory findings from anecdotal reports, and reviewers tend to note the small size and methodological limits of the available studies.
TB-500 refers to a synthetic peptide fragment derived from the actin-binding region of thymosin beta-4, a protein present in most mammalian cells. The full protein contains forty-three amino acids, while the commonly sold fragment is a much shorter acetylated sequence, often cited as LKKTETQ. The fragment retains part of the actin-binding motif but lacks the remainder of the parent protein. Material sold under this name is usually lyophilized powder intended for laboratory research, and it is not a finished pharmaceutical product.
The δ values and absolute isotope ratios of common reference materials are summarized in Table 1 and described in more detail below. Alternative values for the absolute isotopic ratios of reference materials, differing only modestly from those in Table 1, are presented in Table 2.5 of Sharp (2007) (a text freely available online), as well as Table 1 of the 1993 IAEA report on isotopic reference materials. For an exhaustive list of reference material, refer to Appendix I of Sharp (2007), Table 40.1 of Gröning (2004), or the website of the International Atomic Energy Agency. Note that the 13C/12C ratio of Vienna Pee Dee Belemnite (VPDB) and 34S/32S ratio of Vienna Canyon Diablo Troilite (VCDT) are purely mathematical constructs; neither material existed as a physical sample that could be measured.
==== Malaysia ==== Most Malaysian think tanks are related either to the government or a political party. Historically they focused on defense, politics and policy. However, in recent years, think tanks that focus on international trade, economics, and social sciences have also been founded. Notable think tanks in Malaysia include:
Several scandals affected Uribe's administration; the Colombian parapolitics scandal expanded during his second term, involving numerous members of the administration's ruling coalition. Many pro-government lawmakers, such as the President's cousin Mario Uribe, were also investigated for their possible ties to paramilitary organizations. At the end of 2007, FARC agreed to release former senator Consuelo González, politician Clara Rojas, and her son Emmanuel, born in captivity after a relationship with one of her captors. Operation Emmanuel was proposed and set up by Venezuelan President Hugo Chávez, with the permission of the Colombian government. The mission was approved on December 26; however, on December 31, FARC claimed that the hostage release had been delayed because of Colombian military operations. At the same time, Colombian President Álvaro Uribe indicated that FARC had not freed the three hostages because Emmanuel may not be in their hands anymore. Two FARC gunmen were taken prisoner. Colombian authorities added that a boy matching Emmanuel's description had been taken to a hospital in San José del Guaviare in June 2005. The child was in poor condition; one of his arms was hurt, he had severe malnutrition, and he had diseases that are commonly suffered in the jungle. Having been evidently mistreated, the boy was later sent to a foster home in Bogotá, and DNA tests were announced to confirm his identity.
== History == In 1908, what appears to be the first case of Urbach–Wiethe disease was reported by Friedrich Siebenmann, a professor of otolaryngology in Basel, Switzerland. In 1925, Friedrich Miescher, a Swiss dermatologist, reported on three similar patients. An official report of Urbach–Wiethe disease was first described in 1929 by a Viennese dermatologist and otorhinolaryngologist, Urbach and Wiethe. Its original name of 'lipoidosis cutis et mucosae' was changed to 'lipoid proteinosis cutis et mucosae' due to Urbach's belief that the condition was due to abnormal lipid and protein deposits within the tissues. Some have debated as to whether or not the disease is actually a form of mucopolysaccharidosis, amyloidosis, or even porphyria. The discovery of the Urbach–Wiethe disease causing mutation to the ECM1 gene has now provided a definitive way to differentiate Urbach–Wiethe disease from these other conditions. A woman with Urbach–Wiethe disease, S.M., was a woman unable to feel fear. She has been extensively studied, which helped determine the function of the amygdala.
A small proportion is used in medicine or is used industrially for nonfood purposes (e.g. leather) nonfood purposes it is not commonly used for include, chewing gum, skin blankets for the elderly, spare teeth for sheep, and last but not limited to, pablo.
Sources: en.wikipedia.org
=== Additive for cosmetics === The juice can be used in skin creams due to its high polyphenol, vitamin and protein content. Hemp salt unfolds its soothing effect on neurodermatitis as a bath additive. Hemp juice is now appearing as an inactive ingredient in many cosmetic products.
Gestational diabetes resembles type 2 diabetes in several respects, involving a combination of relatively inadequate insulin secretion and responsiveness. It occurs in about 2–10% of all pregnancies and may improve or disappear after delivery. It is recommended that all pregnant women get tested starting around 24–28 weeks gestation. It is most often diagnosed in the second or third trimester because of the increase in insulin-antagonist hormone levels that occurs at this time. However, after pregnancy approximately 5–10% of women with gestational diabetes are found to have another form of diabetes, most commonly type 2. Gestational diabetes is fully treatable, but requires careful medical supervision throughout the pregnancy. Management may include dietary changes, blood glucose monitoring, and in some cases, insulin may be required. Though it may be transient, untreated gestational diabetes can damage the health of the fetus or mother. Risks to the baby include macrosomia (high birth weight), congenital heart and central nervous system abnormalities, and skeletal muscle malformations. Increased levels of insulin in a fetus's blood may inhibit fetal surfactant production and cause infant respiratory distress syndrome. A high blood bilirubin level may result from red blood cell destruction. In severe cases, perinatal death may occur, most commonly as a result of poor placental perfusion due to vascular impairment. Labor induction may be indicated with decreased placental function.
Arrived in Europe in the 16th century, this solanaceous plant (with a pink skinned tuber in England and a yellow skin in Spain) spread in the Principality of Liege, Ireland, Flanders, Germany, Switzerland, Italy, Austria, etc. In France, its resemblance with toxic species (for example the daturas, known for their toxicity to livestock, but also to humans) and the lack of techniques of conservation and use, are brakes to its cultivation, beside purely agronomic reasons (bad ecological adaptation) or religious (non-perception of the tithe on this food). In the Théâtre d'agriculture et Mesnage des champs, published in 1600, Olivier de Serres already recommended the cultivation of the "white truffle" or "cartoufle" and found it to have a flavor worthy of the best black truffles. Around 1750, the cultivation and consumption of tubers were recommended by several people or institutions: Duhamel du Monceau, the bishops of Albi and Léon, the minister Turgot, Rose Bertin, the Agricultural Society of Rennes. Ten years before the publications of Antoine Parmentier and Samuel Engel, Duhamel du Monceau "strongly exhorts farmers not to neglect the cultivation of this plant" and remarks that "it is an excellent food especially with a little bacon and salted pork". But the French population remains more than reticent before this dish: the majority of French people still disdain it as a food for humans, even if it is cultivated and used in some regions.
=== Statehood era === The U.S. conducted underground tests of nuclear weapons on Amchitka Island from 1965 to 1971 as part of the Vela Uniform program. The final detonation, the Cannikin, was the largest underground nuclear explosion by the U.S. The Alaska Native Claims Settlement Act became law in 1971. In 1977, the Ounalashka Corporation (from Unalaska) declared a dividend. This was the first village corporation to declare and pay a dividend to its shareholders. The Aleutian Islands were designated a UNESCO biosphere reserve in 1976. The Aleutians were one of 17 biosphere reserves in the United States withdrawn by request of the U.S. government from the programme in June 2017.
Sources: en.wikipedia.org
==== Compatibility of ABO and Rh system for Red Cell (Erythrocyte) Transfusion ==== This chart shows possible matches in blood transfusion between donor and receiver using ABO and Rh system. The symbol indicates compatibility.
=== Steps of the urea cycle === Carbamoyl phosphate is converted to citrulline. With catalysis by ornithine transcarbamylase, the carbamoyl phosphate group is donated to ornithine and releases a phosphate group. A condensation reaction occurs between the amino group of aspartate and the carbonyl group of citrulline to form argininosuccinate. This reaction is ATP dependent and is catalyzed by argininosuccinate synthetase. Argininosuccinate undergoes cleavage by argininosuccinase to form arginine and fumarate. Arginine is cleaved by arginase to form urea and ornithine. The ornithine is then transported back to the mitochondria to begin the urea cycle again.
If references are made, the Court of Justice will give a preliminary ruling, in order for the member state court to conclude the case and award a remedy. The right to an effective remedy is a general principle of EU law, enshrined in the Charter of Fundamental Rights article 47. Most of the time Regulations and Directives will set out the relevant remedies to be awarded, or they will be construed from the legislation according to the practices of the member state. It could also be that the government is responsible for failure to properly implement a Directive or Regulation, and must therefore pay damages. In Francovich v Italy, the Italian government had failed to set up an insurance fund for employees to claim unpaid wages if their employers had gone insolvent, as the Insolvency Protection Directive required. Francovich, the former employee of a bankrupt Venetian firm, was therefore allowed to claim 6 million Lira from the Italian government in damages for his loss. The Court of Justice held that if a Directive would confer identifiable rights on individuals, and there is a causal link between a member state's violation of EU and a claimant's loss, damages must be paid. The fact that the incompatible law is an Act of Parliament is no defence. So, in Factortame it was irrelevant that Parliament had legislated to require a quota of British ownership of fishing vessels in primary legislation.
=== Public security === The Federal Government presented a proposed constitutional amendment (PEC) aimed at modernizing and integrating public security in the country. The initiative, led by the ministry of justice and public security, Ricardo Lewandowski, seeks to strengthen the fight against organized crime and improve cooperation among the Union, states and municipalities. Among the main points are the creation of a Unified Public Security System (SUSP) with constitutional status, the expansion of the responsibilities of the Federal Police and the Federal Highway Police – which would be renamed the Federal Ostensive Police – and the consolidation of permanent financial instruments, such as the National Public Security and Penitentiary Policy Fund, guaranteeing stable resources for the sector. The government argues that the proposal does not remove the autonomy of the states, but seeks to promote greater coordination and efficiency in police action, especially in the face of the advance of criminal factions operating beyond state borders. Even so, the text faces resistance from sectors of the right and the opposition. Despite the criticism, the Ministry of Justice states that the proposal was built in dialogue with governors and specialists, and that it represents an effort to make the fight against crime more integrated, technological and effective throughout the national territory.
Mifamurtide (trade name Mepact, marketed by Takeda) is a drug against osteosarcoma, a kind of bone cancer mainly affecting children and young adults, which is lethal in over half of cases. The drug was approved in Europe in March 2009.
Sources: en.wikipedia.org
No. Thymosin beta-4 is a 43-residue protein, while TB-500 matches only residues 17 to 23 of that chain. The two are related but differ in size, and a method that identifies one does not automatically identify the other.
It corresponds to the actin-binding region of thymosin beta-4. Commercial synthesis reproduces that seven-residue stretch, usually with an acetyl group on the N-terminus.
It is not authorised as a medicine in the United States or the European Union and is distributed as a research chemical. Labels consequently carry research-use-only statements rather than clinical indications.
It is a synthetic peptide based on a short sequence near the start of thymosin beta-4. It is supplied as a research chemical rather than as a licensed pharmaceutical product.